Other languages Equillium, Inc.

Equities

EQ

US29446K1060

Delayed Nasdaq Other stock markets 12:57:09 2024-04-29 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-3.51%		0.00%	+128.22%

Apr. 02	H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	MT
Apr. 01	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21
Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13
Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology	Nov. 06
Equillium, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer	23-08-09
Equillium Board Approves $7.5 Million Share Buyback Program	23-08-03
Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.	23-08-02
Equillium, Inc. authorizes a Buyback Plan.	23-08-01
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Equillium Files $250 Million Mixed Shelf	23-01-09
Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. from a group of shareholders.	22-12-22
Equillium Partner Biocon Initiates Phase 2 Study of Itolizumab to Treat Ulcerative Colitis	22-12-16
Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis	22-12-16
Biocon Begins Phase-2 Clinical Trial of Itolizumab for Ulcerative Colitis	22-12-14
Equillium Offers Ono Pharmaceuticals Rights to Investigational Treatment for Immuno-Inflammatory Diseases	22-12-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Equillium, Inc.

Equities

EQ

US29446K1060

Other languages

Filters